OBJECTIVES:
Our objective was to determine the least costly strategy for treatment of postmenopausal (PMP) women with the primary complaint of dysuria.
MATERIALS AND METHODS:
We performed a cost minimization analysis modeling the following clinical options: (1) empiric antibiotic therapy (eABX) followed by urine culture (Ucx), (2) E. coli, E. faecalis, K. pneumonaie, or P. mirabalis. Pathogens, resistance, treatment success, and medication side effects were specific to postmenopausal women. RESULTS: In terms of our results, we assumed 73.4% of UTIs were caused by E.coli strains with a 24.4% resistance to TMP/SMX. With our assumptions, eABX TMP/SMX was the least costly approach ($89.64/patient, Table 1), followed by waiting for Ucx($97.04/patient). For any given antibiotic, eABX was always less costly than using U/A first. This is due to cost of U/A ($38.23), high rate of UTI (90%) in PMP women with dysuria, and resultant high rate of ABX with or without U/A. Options with fosfomycin were the most expensive due to highest drug costs($98/dose), and tornado analyses showed fosfomycin cost was the most impactful variable for model outcomes. Sensitivity analyses showed eABX fosfomycin became the least costly option if drug costs were $25.80. This outcome was largely predicated on low resistance to fosfomycin. Conversely, ciprofloxacin was never the least costly option due to higher resistance and side effect cost, even if the drug cost was $0. CONCLUSION: In conclusion, the least costly strategy was eABX TMP/ SMX, followed by waiting on Ucx. Local resistance patterns will impact cost minimization strategies. Fosfomycin eABX would be least costly with reduced drug costs. In a population with high posttest probability of positive Ucx, U/A adds unnecessary cost. Antibiotic stewardship should continue efforts to decrease fluoroquinolone use due to high resistance, side effects, and increased cost.
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